Table 2. Animal survival after stem cell application.
| Survival rate, n/N (%) | ||||
|---|---|---|---|---|
| First author | Animal model/Stem cell | Treatment | Control | p value |
| Lee, 2004(30) | Chicken embryo/Human ESCs | POD 3, NR | POD 4, NR | >0.05 |
| POD 5, NR | POD 6, NR | >0.05 | ||
| POD 7, NR | POD 8, NR | <0.05 | ||
| Lee, 2006(31) | Chicken embryo/Human ESCs | POD 4, 15/19 (78.9%) | POD 4, 15/18 (83.3%) | 0.73 |
| POD 6, 15/21 (71.4%) | POD 6, 15/19 (78.9%) | 0.58 | ||
| POD 8, 15/23 (65.2%) | POD 8, 15/22 (68.2%) | 0.83 | ||
| Li, 2012(33) | Wistar rat/Wistar rat BM-MSCs | 152/195 (77.9%) | NA | NA |
| Li, 2014(34) | Wistar rat/Wistar rat BM-MSCs | 18/22 (81.8%) | NA | NA |
| Ma, 2015(35) | Wistar rat/Wistar rat BM-MSCs | 58/72 (80.6%) | NA | NA |
| Li, 2016(36) | Wistar rat/Wistar rat BM-MSCs | 69/134 (51.5%) | NA | NA |
| Wei, 2020a(37) | Wistar rat/Wistar rat BM-MSCs | 30/30 (100%) | 23/23 (100%) | 1.00 |
| Wei, 2020b(38) | Wistar rat/Wistar rat BM-MSCs | 32/32 (100%) | 28/28 (100%) | 1.00 |
| Turner, 2013(48) | Lewis rat/Lewis rat AF-NSCs | 20/37 (54.1%) | NA | NA |
| Dionigi, 2Ol5a(39) | Sprague-Dawley rat/Lewis rat AF-MSCs | 28/82 (34.1%) | NA | NA |
| Feng, 2016(41) | Sprague-Dawley rat/Lewis rat AF-MSCs and P-MSCs | AF-MSCs, 65/73 (89.0%) | 30/38 (78.9%) | 0.15 |
| P-MSCs, 90/115 (78.3%) | 0.93 | |||
| Shieh, 2018(42) | Sprague-Dawley rat/Lewis rat AF-MSCs | 70/78 (89.7%) | 62/66 (93.9%) | 0.77 |
| Lazow, 2020(43) | Sprague-Dawley rat/Lewis rat AF-MSCs | 36/105 (34.3%) | 34/107 (31.8%) | 0.70 |
| Abe, 2019(44) | Sprague-Dawley rat/Human AF-MSCs | 19/22 (86.4%) | 17/19 (89.5%) | 0.76 |
| Kajiwara, 2017(45) | Sprague-Dawley rat/3D skin from human AF-derived iPSCs | 20/20 (100%) | NA | NA |
| Shieh, 2019(46) | New Zealand rabbit/New Zealand rabbit AF-MSCs | 10/35 (28.6%) | 5/15 (33.3%) | 0.74 |
| Fauza, 2008(47) | Ovine/Mice cerebellum NSCs | 8/9 (88.8%) | 6/7 (85.7%)a | 0.85 |
| Saadai, 2013(49) | Ovine/Human NCSCs derived from iPSCs | 2/2 (100%) | NA | NA |
| Wang, 2015(50) | Ovine/Human P-MSCs | 6/6 (100%) | 6/6 (100%)a | 1.00 |
| Brown, 2016(51) | Ovine/Human P-MSCs | 2/2 (100%) | 1/1 (100%)a | 1.00 |
| Vanover, 2019(54) | Ovine/Human P-MSCs | 19/22 (86.4%) | 8/8 (100%)a | 0.55 |
Abbreviations: AF-MSCs, amniotic fluid-derived mesenchymal stem cells; CRL, crown-rump length; NA, not available; NR, exact data are not retrievable after contact with corresponding author; P-MSCs, placental-derived mesenchymal stem cells; POD, postoperative day.
a
Fetal MMC surgical repair as a control group.